Interestingly, niclosamide has been repurposed as a STAT3 inhibitor in CRC treatment (80), and STAT3, an important therapeutic target, has recently been found to be meditated by sialylated c-Met in CRC (81). This evidence concerns the gene MET and colorectal carcinoma.